A systematic literature review was conducted in October 2017 looking at evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. This included 6 randomized controlled trials (RCT) and 30 observational studies. Data suggests that cannabinoids may be an effective adjuvant treatment for reducing seizure frequency.

This paper is a review of nine published literature on the efficacy of vitamin D intervention on bone health in adults with epilepsy. While there did appear to be positive changes in bone turnover markers, the varying methodologies used in each study made the impact of vitamin D on bone mineralization inconclusive.

It has been shown that cannabidiol (CBD) can alleviate certain epilepsies, however its pharmacological profile is unknown. The authors tested whether the anticonvulsant effects of CBD would be prevented by cannabinoid and vanilloid receptor blockers to help determine its pharmacological profile.

The ketogenic diet has shown to be successful in reducing seizures in pharmaco-resistant epilepsy patients, however it is highly unpalatable and difficult to follow. A new diet which combines medium-chain fatty acids, polyunsaturated fatty acid, low glycemic index carbohydrates, and a high BCAA/AAA ratio has shown to reduce excitatory drive and produce results similar to the ketogenic diet.

This paper summarizes current literature on the cannabinoid effects in animal models of seizures.

A retrospective study was conducted in five Israeli pediatric clinics examining the effect of cannabidiol (CBD) on children with intractable epilepsy. The results showed that CBD had a positive effect on seizure load and also was associated with improvements in behavior, language, communication, motor skills, and sleep. Some adverse events were also reported which included drowsiness, fatigue, gastrointestinal disturbances and irritability. Further clinical trials using CBD are warranted to validate these findings.